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Summary
Background: Recently, serum beta2-microglobulin, an endogenous marker for renal function,
has been shown to be an independent predictor of mortality in older adults. However, the
prognostic role of beta2-microglobulin in heart failure has not been elucidated.
Methods: We prospectively evaluated serum beta2-microglobulin and creatinine concentra-
tions, creatinine-based renal parameters (estimated glomerular ﬁltration rate and creatinine
clearance), and echocardiographic data in 131 patients with acute heart failure and creatinine
concentrations ≤3.0mg/dL admitted to our hospitals.
Results: During 2.3± 1.3 years, 42 patients died of cardiovascular causes and 12 died of non-
cardiac causes. Cardiovascular events were observed in 63 patients: 53 were readmitted due to
worsening heart failure, 5 readmitted for cerebral embolism, and 5 died from sudden cardiac
death. According to multivariate stepwise Cox proportional hazard analysis, higher baseline
serum beta2-microglobulin concentrations (X2 = 16, p < 0.0001), previous congestive heart fail-
ure (X2 = 11, p < 0.001), presence of chronic obstructive pulmonary disease (X2 = 8, p < 0.01),
and lower diastolic blood pressure (X2 = 6, p < 0.05) were independent predictors of increased
cardiovascular events. Also, higher baseline serum beta2-microglobulin (X2 = 20, p < 0.0001),
lower systolic blood pressure (X2 = 11, p < 0.001), higher relative left ventricular wall thickness
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(X2 = 6, p < 0.05), and lower body mass index (X2 = 5, p < 0.05) were independent predictors
of increased cardiac mortality. The adjusted hazard ratio for cardiovascular events increased
with baseline serum beta2-microglobulin above 2.1mg/L: 2.9 with beta2-microglobulin of
2.2—2.6mg/L (95%CI 1.2—6.9, p < 0.05), 2.9 with beta2-microglobulin of 2.7—3.9mg/L (95%CI
1.2—7.2, p < 0.05), and 4.7 with beta2-microglobulin of ≥4.0mg/L (95%CI 2.0—11, p < 0.001).
Conclusions: Higher baseline serum beta2-microglobulin concentration could be a promising risk
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weight in kg)/(72× serum creatinine in mg/dL). For women,
the calculated values were multiplied by 0.85.
We obtained all of the data for each patient on the samemarker in acute heart failure
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ecent studies have underscored the importance of renal
unction parameters, namely estimated glomerular ﬁltra-
ion rate (eGFR) [1,2], creatinine clearance [3,4], and
ystatin-C [5—7], as strong predictors of mortality and
ardiac events in heart failure. Plasma levels of two
ow molecular weight proteins, cystatin-C and beta2-
icroglobulin, are indicators of GFR [8,9]. A recent study
10] showed serum beta2-microglobulin to be an indepen-
ent predictor of total mortality in a general population of
lder adults, and a better predictor than cystatin-C. How-
ver, the prognostic role of serum beta2-microglobulin in
atients with heart failure has not been elucidated.
In this prospective study, we evaluated serum beta2-
icroglobulin as a predictor for long-term outcome in
cute heart failure. We also compared the ability of beta2-
icroglobulin to determine risk in acute heart failure
atients with creatinine-based renal parameters.
ethods
tudy patients
etween January 2000 and January 2005, 131 consecu-
ive congestive heart failure patients (77± 11 years of age)
dmitted to Kasai City Hospital or Kanzaki General Munici-
al Hospital, or followed up in the outpatient clinics, were
xamined. Among the 131 patients, 7 who rejected admis-
ion [New York Heart Association (NYHA) functional class
I/III: 3/4] were recruited in outpatient clinics. The study
as approved by the appropriate institutional review board,
nd all patients provided informed consent.
Congestive heart failure was conﬁrmed according to
ramingham criteria [11], which include nocturnal dyspnea,
rthopnea, dyspnea on exertion, edema, and pulmonary
ales due to pulmonary congestion conﬁrmed by chest
adiography. We excluded patients with acute coronary syn-
rome, right ventricular failure, critical aortic or mitral
tenosis, and severe renal dysfunction (i.e. plasma creati-
ine concentration >3.0mg/dL) [1]. Patients with plasma
-type natriuretic peptide (BNP) concentrations <50 pg/mL
ere excluded due to a low probability of acute heart fail-
re [12,13]. Hypertension, ischemic heart disease, diabetes,
nd chronic obstructive pulmonary disease (COPD) were
eﬁned as previously described [13]. In the present study, 4
atients had previously undergone surgery for cancer, and
had concurrent malignancies (total 11 patients: 3 with
tomach cancer, 1 with colon cancer, 1 lung cancer, 1 malig-
ant lymphoma, and others), and 1 patient had rheumatoid
rthritis.
d
m
d
t
hients with creatinine ≤3.0mg/dL.
ology. Published by Elsevier Ireland Ltd. All rights reserved.
chocardiograph study
aseline echocardiography was performed on each of all
31 patients using a Toshiba Sonolayer SSH 160A or SSA
50A (Toshiba Medical, Tokyo, Japan) or Hitachi ultra-
ound scanner EUB 6000 (Hitachi Medical, Tokyo, Japan).
eft ventricular (LV) end-diastolic dimension, the dias-
olic thickness of the ventricular septum and the posterior
V wall, LV mass index, and relative LV wall thick-
ess [(septal thickness + posterior LV wall thickness)/LV
nd-diastolic dimension] were determined as previously
escribed [14,15]. In patients with sinus rhythm, early-
o-atrial transmitral peak velocity ratio was measured as
reviously described [16]. The systolic pressure gradient
etween the right atrium and right ventricle, which pre-
umes systolic pulmonary arterial pressure, was calculated
rom the velocity of tricuspid regurgitation. Pulmonary
ypertension was deﬁned as a ≥30mmHg systolic pressure
radient between the right atrium and ventricle. LV ejec-
ion fraction (EF) was determined by Teichholz’s formula in
atients without signiﬁcant regional wall motion abnormal-
ties. In patients with regional wall motion abnormalities,
e assessed LVEF with the modiﬁed Simpson’s rule [17] or
y visual estimation [18].
aboratory measurements
lasma BNP concentration was run fresh and deter-
ined by an immunoradiometric assay using an antibody
o human BNP (Shionogi, Osaka, Japan) [19]. We mea-
ured serum blood urea nitrogen and creatinine (the
nzyme method) concentration with routine commer-
ial enzyme assay kits. We used a latex agglutination
hotometric immunoassay to determine serum concentra-
ions of beta2-microglobulin (normal range 1.0—1.9mg/L,
iken Chemicals, Tokyo, Japan). We estimated GFR
mL/min/1.73m2) with the abbreviated modiﬁcation of diet
n renal disease (MDRD) equation modiﬁed by a Japanese
oefﬁcient [20]: eGFR = 0.741× 175× [serum creatinine in
g/dL]−1.154 × [age in years]−0.203. For women, the cal-
ulated values were multiplied by 0.742. We estimated
reatinine clearance (mL/min) with the Cockroft—Gault
quation: creatinine clearance = ([140− age in years]×bodyay (n = 131). For 104/131 (79%) patients, the laboratory
easurements were obtained within 3 days of echocar-
iography. Also, for 98/124 (79%) hospitalized patients,
he laboratory measurements were taken within the 3rd
ospital day. The laboratory data from the remaining 26
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5Figure 1 Outcome after treatment
patients were taken at the median 5th (4—16th) hospital
day.
Endpoints and follow-up
The endpoints were (1) cardiovascular events, deﬁned as
sudden cardiac death and hospital admission due to heart
failure or cardiovascular complications, and (2) cardiac
death, deﬁned as death from cardiovascular causes.
Patients were prospectively followed up for an average
of 2.3± 1.3 years. For 94/131 (72%) patients, a sec-
ond set of echocardiography and laboratory measurements
was obtained an average of 7± 7 weeks after treatment
(Fig. 1).
Statistical analysis
We compared data from heart failure patients with car-
diac events to event-free patients during follow-up. Group
averages are expressed as means± standard deviation (SD),
unless otherwise speciﬁed. BNP concentration was not
normally distributed, and is expressed as median and
interquartile range. Group comparisons of BNP values were
performed with non-parametric tests. p-Values < 0.05 were
considered signiﬁcant. The associations of the variables
with cardiac events or mortality were determined with a
Cox proportional hazard analysis. Only variables with a p-
value < 0.05 in the univariate Cox analysis were included
in a multivariate stepwise Cox analysis. Forward stepwise
selection manner, with both values for inclusion and elim-
ination set at p = 0.05, was used to create a ﬁnal reduced
model for predicting outcomes. For cardiac events, 20 signif-
icant variables were entered into the multivariate analysis:
baseline variables (age, diastolic blood pressure, blood urea
nitrogen, creatinine, beta2-microglobulin, eGFR, creatinine
f
d
d
u31 patients with acute heart failure.
learance, ischemic heart disease, previous myocardial
nfarction, previous congestive heart failure, COPD, and
ancer) and post-treatment variables (NYHA class, pul-
onary hypertension, BNP, blood urea nitrogen, creatinine,
eta2-microglobulin, eGFR, and creatinine clearance). The
roportional hazards assumption was checked with a log
inus log plot.
The association of each variable with baseline serum
eta2-microglobulin concentration was evaluated with a
nivariate linear regression analysis. Variables with a p-
alue < 0.05 were entered into a multivariate stepwise
egression.
We evaluated the association of quartiles of renal param-
ters as predictors of cardiac events. We determined the
nadjusted and multivariate-adjusted risk for quartiles 2
hrough 4 compared with quartile 1. Adjusted cardiac event-
ree survival curves were constructed for the quartiles of
erum beta2-microglobulin after adjustment for all covari-
tes. Data with missing data points were excluded from
nalysis. Data was analyzed using SPSS 11.0 software (SPSS,
hicago, IL, USA).
esults
ong-term outcome, baseline characteristics and
ost-treatment data in heart failure patients
uring the 2.3± 1.3 years after initiation of the study, car-
iovascular events were observed in 63/131 (48%) patients:
3 (40%) patients were readmitted due to worsening heart
ailure, 5 (4%) readmitted for cerebral embolism, and 5 (4%)
ied from sudden cardiac death.
During follow-up, 54/131 (41%) patients died: 42 (32%)
ied of cardiovascular causes (33 from worsening heart fail-
re, 2 fromworsening cerebral embolism, and 7 from sudden
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ardiac death). Namely 2 patients died suddenly after dis-
harge from hospital readmission due to worsening heart
ailure; 12 (9%) died of noncardiac causes (7 from cancer, 4
rom pneumonia, and 1 phlegmon) (Fig. 1).
Comparisons of the baseline characteristics of patients
ith cardiac events and event-free patients are presented
n Table 1. Baseline characteristics associated with cardiac
vents were advanced age, lower diastolic blood pressure,
educed body surface area, higher blood urea nitrogen,
reatinine, and beta2-microglobulin, lower eGFR and creati-
ine clearance, ischemic heart disease, previous myocardial
nfarction, previous congestive heart failure, and less use of
asodilators at baseline.
After treatment, the NYHA functional class (I/II/III/IV
ost-treatment: 1/47/1/1 in event-free patients and
/35/7/0 in patients with cardiac events) and BNP con-
entration [median (25th, 75th percentiles) post-treatment:
00 (80, 284) pg/mL in event-free patients and 255
155, 498) pg/mL in patients with cardiac events]
ecreased in both groups of patients (p < 0.0001). Serum
eta2-microglobulin concentration increased (p < 0.05) in
oth groups (2.9± 1.4mg/L in event-free patients and
.4± 2.3mg/L in patients with cardiac events).
redictors for long-term outcome
ll the variables listed in Table 1 at baseline and after
reatment were analyzed using univariate Cox proportional
azard analysis. Among the variables, 20 (see Methods sec-
ion) and 19 (not shown) were signiﬁcant predictors of
ardiac events and cardiac mortality, respectively.
As shown in Table 2, at baseline, serum beta2-
icroglobulin concentration was the most powerful predic-
or of cardiac events and cardiac mortality, as expressed
y a chi-square value. A 1.58mg/L (1 SD) increase in
erum beta2-microglobulin was associated with a 1.5-fold
ncreased risk of cardiac events. Previous congestive heart
ailure, presence of COPD and lower diastolic blood pres-
ure were also independently associated with an increased
isk of cardiac events. Likewise, lower systolic blood pres-
ure, higher relative LV wall thickness, and lower body mass
ndex were also independently associated with an increased
isk of cardiac mortality.
In several types of malignancies [21,22], it was reported
hat adverse prognosis is associated with higher serum
eta2-microglobulin concentration. Even if 11 patients with
revious or concurrent malignancies were excluded from
he analysis, serum beta2-microglobulin was still a strong
nd independent predictor of cardiac events and cardiac
ortality (middle section of Table 2). In the multivariate
ox analysis including both baseline and post-treatment
ariables, baseline serum beta2-microglobulin was again a
trong predictor of outcome (bottom section in Table 2).
igher BNP concentration post-treatment also indepen-
ently contributed to increased cardiac mortality.ariables associated with baseline serum
eta2-microglobulin concentration
levated serum beta2-microglobulin has been reported in
atients with a variety of non-renal illnesses, including solid
S
l
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alignancies, leukemia, and rheumatic diseases [23,24]. To
larify the effects on serum beta2-microglobulin, all the
arameters listed in Table 1 were evaluated by linear regres-
ion (Table 3). According to a multivariate stepwise linear
egression analysis, age, sex, and serum creatinine were
igniﬁcant independent determinants of baseline serum
eta2-microglobulin concentrations. According to the stan-
ardized coefﬁcient, serum creatinine had a greater impact
n serum beta2-microglobulin than age or sex. The square of
he multivariate correlation coefﬁcient (R2) indicated that
hese three parameters accounted for 73% of serum beta2-
icroglobulin concentration.
uartiles of renal parameters and cardiac-event
isk
ext we compared the ability of beta2-microglobulin to dis-
inguish cardiac-event risk with other renal parameters. As
hown in Table 4, after multivariate adjustment, the 4th
uartile (≥4.0mg/L) of baseline beta2-microglobulin was
ssociated with a 4.7-fold increased cardiac-event risk com-
ared to the 1st quartile (≤2.1mg/L). Although the 4th
uartiles of baseline creatinine and creatinine clearance
ere associated with a signiﬁcantly greater adjusted event
isk than the 1st quartile, besides the highest quartile,
he 2nd and 3rd quartiles of beta2-microglobulin were also
elated to an increased risk for cardiac events. Adjusted car-
iac event-free survival curves according to the quartile of
eta2-microglobulin are shown in Fig. 2.
iscussion
n the present study, we showed that a higher base-
ine concentration of serum beta2-microglobulin was the
ost powerful predictor of cardiac events and cardiac
ortality in acute heart failure patients with creatinine
3.0mg/dL. Furthermore, we demonstrated that baseline
erum beta2-microglobulin concentration had a superior
bility to distinguish cardiac-event risk in acute heart failure
atients compared with creatinine-based renal parame-
ers. The association of baseline concentration of serum
eta2-microglobulin with cardiovascular events or cardiac
ortality was still obtained when patients with cancer were
xcluded from analysis.
isk factors for prognosis
n addition to beta2-microglobulin, several other risk factors
or outcome were identiﬁed in this study (Table 2). Prognos-
ic values of previous heart failure [25], COPD [26], systolic
7,27] and diastolic blood pressure [25], and bodymass index
5,25,27] in heart failure were conﬁrmed previously. Post-
reatment BNP levels [28,29] also have been reported to be
trong predictors of mortality in heart failure.erum beta2-microglobulin as a predictor of
ong-term outcome
idely distributed in nucleated cells in the body and
hed into the circulation, beta2-microglobulin is ﬁltered
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Table 1 Patient baseline characteristics by cardiac events during follow-up.
Events (−) (n = 68) Events (+) (n = 63) p-Value
Age (years) 74± 12 81± 9 0.002
Male 28 (41%) 25 (40%) 0.9
NYHA class II/III/IV 7/35/26 5/36/22 0.9
SBP (mmHg) 142± 27 133± 26 0.06
DBP (mmHg) 80± 14 73± 15 0.006
Heart rate (beats/min) 78± 17 81± 20 0.5
Body surface area (m2) 1.54± 0.24 1.46± 0.18 0.04
Body mass index (kg/m2) 23± 5 22± 3 0.07
Echocardiograph data
LVEDD (mm) 54± 10 52± 9 0.3
LVEF (%) 51± 18 50± 16 0.6
LV mass index (g/m2) 150± 52 152± 48 0.9
Septal thickness (mm) 10.8± 2.8 10.9±2.5 0.9
Posterior wall thickness (mm) 10.6± 2.1 10.9± 1.9 0.4
Relative LV wall thickness 0.41± 0.11 0.44± 0.12 0.2
Left atrial diameter (mm) 50± 10 50± 10 1.0
E/Aa 1.1± 0.7 1.1± 0.7 1.0
Pulmonary hypertension 31(47%) 34 (54%) 0.4
Laboratory data
BNP (pg/mL)b 423 (208, 940) 552 (328, 1040) 0.15
BUN (mg/dL) 21± 10 25± 13 0.03
Creatinine (mg/dL) 0.9± 0.4 1.1± 0.5 0.01
Beta2-microglobulin (mg/L) 2.8± 1.3 3.6± 1.7 0.002
eGFR (mL/min/1.73m2)c 61± 23 50± 22 0.006
Creatinine clearance (mL/min)c 62± 38 43± 22 0.0009
Medical history
Hypertension 40 (59%) 31 (49%) 0.3
Ischemic heart disease 13 (19%) 26 (41%) 0.006
Previous myocardial infarction 10 (15%) 21 (33%) 0.01
Previous CHF 17 (25%) 33 (52%) 0.001
Diabetes mellitus 16 (24%) 15 (24%) 1.0
COPD 4 (6%) 6 (10%) 0.4
Valvular heart disease 32 (47%) 32 (51%) 0.7
Atrial ﬁbrillation 30 (44%) 34 (54%) 0.3
Cancerd 4 (6%) 7 (11%) 0.3
Use of medication at baseline
ACE-inhibitors or ARB 28% 33% 0.5
Beta-blockers 15% 19% 0.5
Digitalis 16% 29% 0.09
Diuretics 50% 65% 0.08
Vasodilators 29% 14% 0.04
Nitrates 40% 37% 0.7
Use of medication after treatmente
ACE-inhibitors or ARB 82% 82% 1.0
Beta-blockers 68% 55% 0.2
Digitalis 32% 36% 0.7
Diuretics 82% 89% 0.4
Vasodilators 20% 7% 0.07
Nitrates 28% 46% 0.08
Data are expressed as mean± SD, number and/or percent of patients, or median (25th, 75th) percentiles. ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blockers; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; E/A, early-to-atrial transmitral peak velocity ratio; EDD,
end-diastolic dimension; EF, ejection fraction; eGFR, estimated glomerular ﬁltration rate; LV, left ventricular; NYHA, New York Heart
Association; SBP, systolic blood pressure.
a Data from patients with atrial ﬁbrillation were excluded.
b Median and (25th, 75th percentiles) are shown.
c eGFR was calculated by the abbreviated modiﬁcation of diet in renal disease (MDRD) equation modiﬁed by a Japanese coefﬁcient;
creatinine clearance was by the Cockroft—Gault equation (see Methods section).
d Patients who had previously undergone surgery for cancer (n = 4) or had concurrent malignancies (n = 7) at baseline.
e Data of medication use after 7± 7 weeks from 94 patients for whom follow-up measurements were available.
104 K. Kawai et al.
Table 2 Multivariate stepwise Cox proportional hazard analysis of risk factors for prognosis.
Variable Cardiac events Cardiac mortality
X2 HR (95%CI) X2 HR (95%CI)
Models including only baseline variables (n = 130)
Beta2-microglobulin (per 1.58mg/L increase)a 16 1.5 (1.2—1.8)**** 20 1.8 (1.4—2.4)****
Previous CHF 11 2.4 (1.4—4.0)***
COPD 8 3.9 (1.6—9.7)**
Diastolic blood pressure (per 15mmHg increase)a 6 0.7 (0.5—0.9)*
Systolic blood pressure (per 27mmHg increase)a 11 0.6 (0.4—0.8)***
Relative LV wall thickness (per 0.116 increase)a 6 1.5 (1.1—2.0)*
Body mass index (per 4.2 kg/m2 increase)a 5 0.6 (0.4—0.9)*
Models excluding patients with previous or concurrent malignancies (n = 119)
Beta2-microglobulin (per 1.58mg/L increase)a 16 1.5 (1.2—1.9)**** 10 1.7 (1.2—2.4)**
Previous CHF 11 2.5 (1.4—4.3)**
COPD 9 4.1 (1.6—10)**
Diastolic blood pressure (per 15mmHg increase)a 5 0.7 (0.5—1.0)*
Systolic blood pressure (per 27mmHg increase)a 11 0.5 (0.3—0.8)**
Body mass index (per 4.2 kg/m2 increase)a 6 0.6 (0.3—0.9)*
Blood urea nitrogen (per 12mg/dL increase)a 5 1.5 (1.0—2.0)*
Models including both baseline and post-treatment variables (n = 84—91)
Previous CHF 11 3.2 (1.6—6.5)***
Baseline beta2-microglobulin (per 1.58mg/L increase)a 9 1.5 (1.2—2.0)** 20 1.9 (1.4—2.8)****
Cancer 6 5.0 (1.4—17)*
COPD 5 4.1 (1.2—14)*
Age (per 11 years increase)a 4 1.6 (1.0—2.5)*
Baseline diastolic blood pressure (per 15mmHg increase)a 10 0.5 (0.3—0.8)**
Post-treatment BNP (per 125 pg/mL increase)b 6 1.1 (1.0—1.5)*
Beta2-microglobulin and BNP were modeled as continuous variables. BNP, B-type natriuretic peptide; CHF, congestive heart failure; CI,
conﬁdence interval; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; LV, left ventricular; X2, chi-square value.
a Per 1 SD unit.
b Per 1 median absolute deviation (MAD) unit (as BNP concentration was not normally distributed).
* p < 0.05 and ≥0.01.
** p < 0.01 and ≥0.001.
*** p < 0.001 and ≥0.0001.
**** p < 0.0001.
Table 3 Baseline variables associated with baseline serum beta
variate and multivariate (n = 130, R2 = 0.73) analyses.
Variable 2-MG (univariate) 
r () p-Value C
Age (years) 0.4 <0.0001
Male −0.2 0.009 −
SBP 0.2 0.01
BUN 0.6 <0.0001
Creatinine (mg/dL) 0.8 <0.0001
eGFR −0.7 <0.0001
Creatinine clearance −0.5 <0.0001
Use of diuretics 0.3 0.003
R2, square of themultivariate correlation coefﬁcient. was used for non
glomerular ﬁltration rate; SBP, systolic blood pressure.
a Linear regression coefﬁcient.
b The standardized coefﬁcient describes the unit-independent contri2-microglobulin (2-MG) concentration (mg/L) based on uni-
2-MG (multivariate)
oefﬁcienta Standardized coefﬁcientb p-Value
0.023 0.16 0.002
0.56 −0.18 0.001
0.8
0.6
2.83 0.78 <0.001
0.5
0.3
0.13
-parametric variables. BUN, blood urea nitrogen; eGFR, estimated
bution of the independent variable to the model.
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Table 4 Quartiles of baseline renal parameters and cardiac-event risk in patients with acute heart failure.
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile
Beta2-microglobulin
Range (mg/L) ≤2.1 2.2—2.6 2.7—3.9 ≥4.0
n 35 31 32 33
1-year event rate (%)a 8 23 23 31
Unadjusted HR (95%CI) 1.0 2.9 (1.3—6.6)* 3.6 (1.6—8.1)** 4.0 (1.8—8.9)***
Adjusted HR (95%CI)a 1.0 2.9 (1.2—6.9)* 2.9 (1.2—7.2)* 4.7 (2.0—11)***
Creatinine
Range in women (mg/dL) ≤0.67 0.68—0.84 0.85—1.21 ≥1.22
Range in men (mg/dL) ≤0.75 0.76—0.88 0.89—1.10 ≥1.11
n 32 34 33 32
1-year event rate (%)a 9 12 35 31
Unadjusted HR (95%CI) 1.0 0.7 (0.3—1.6) 1.4 (0.7—2.9) 1.9 (0.9—3.7)
Adjusted HR (95%CI)a 1.0 0.8 (0.4—1.8) 2.1 (1.0—4.5) 2.3 (1.0—5.1)*
Estimated GFR
Range (mL/min/1.73m2) ≥70.5 54.3—70.4 38—54.2 ≤37
n 32 33 33 33
1-year event rate (%)a 9 20 33 25
Unadjusted HR (95%CI) 1.0 1.0 (0.4—2.1) 1.7 (0.8—3.5) 2.2 (1.1—4.4)*
Adjusted HR (95%CI)a 1.0 1.1 (0.5—2.4) 2.0 (0.9—4.4) 2.1 (1.0—4.8)
Creatinine clearance
Range (mL/min) ≥66.2 48.7—66.1 30—48.6 <30
n 32 33 33 33
1-year event rate (%)a 6 21 21 43
Unadjusted HR (95%CI) 1.0 2.2 (0.9—5.2) 2.4 (1.0—5.7)* 4.8 (2.2—11)***
Adjusted HR (95%CI)a 1.0 2.3 (0.9—5.7) 2.4 (0.9—6.6) 5.1 (1.7—15)**
GFR, glomerular ﬁltration rate; HR, hazard ratio.
a Adjusted for all baseline covariates besides renal parameters with p < 0.05 in univariate Cox analysis (age, diastolic blood pressure,
ischemic heart disease, previous congestive heart failure, chronic obstructive pulmonary disease, and cancer).
* p < 0.05 and ≥0.01.
** p < 0.01 and ≥0.001.
*** p < 0.001.by glomeruli and reabsorbed by the proximal tubular cells
where it is metabolized. Its plasma concentration increases
with renal dysfunction, and may be a surrogate marker
of GFR [8,9,24,30]. Indeed, as shown in Table 3, beta2-
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Figure 2 Adjusted cardiac event-free survival curves in acute
microglobulin concentrations. The data were adjusted for difference
ischemic heart disease, previous congestive heart failure, chronic obicroglobulin concentration strongly correlated with eGFR
nd creatinine clearance, and was determined by creati-
ine, age, and sex, in accordance with previous studies
8,9,23]. Although eGFR and creatinine clearance values
heart failure patients according to baseline serum beta2-
s in baseline variables, including age, diastolic blood pressure,
structive pulmonary disease, and cancer.
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ere also based on creatinine concentration, age, and sex
see Methods section), serum beta2-microglobulin was a bet-
er prognostic marker for acute heart failure patients than
hese creatinine-based measures (Table 4).
First, recent reports [31,32] showed that GFR could
ot be estimated accurately with the abbreviated MDRD
r Cockroft—Gault equations in persons with normal serum
reatinine concentrations, as the correlation between mea-
ured GFR and estimated GFR was weak (R2 ≤ 0.40). The
ow body mass index observed in our patients (Table 1)
uggested the possibility of malnourishment. Therefore,
ethods based on creatinine (mean 1.0± 0.4mg/dL in the
resent study) may overestimate actual GFR, while serum
eta2-microglobulin would not be affected by reduced mus-
le mass [8].
Second, serum creatinine concentration, age, and sex
ccounted for 73% of serum beta2-microglobulin concen-
ration (R2 = 0.73, Table 3). Regarding the remaining 27%
f beta2-microglobulin, several diseases, including malig-
ancies and inﬂammatory diseases, show an increased
roduction of beta2-microglobulin, resulting in increased
erum concentration despite normal GFR [23,24]. Of note, a
ecent study [10] demonstrated a signiﬁcant (p < 0.001) asso-
iation of serum beta2-microglobulin concentration with
erum high-sensitivity C-reactive protein levels in a healthy,
lder cohort, suggesting that serum beta2-microglobulin
eﬂects low-grade inﬂammation. Therefore, serum beta2-
icroglobulin concentration may also reﬂect factors other
han renal function that are related to mortality.
imitations
lthough the prognostic value of beta2-microglobulin in
his study was statistically highly signiﬁcant, the number
f patients was small. Further studies in a large number of
atients are needed to conﬁrm the prognostic role of serum
eta2-microglobulin in acute heart failure.
onclusions
igher baseline serum beta2-microglobulin concentration
ould be a promising risk marker in acute heart failure
atients with creatinine ≤3.0mg/dL.
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